Document Detail


Usefulness of fibrinogen/fibrin degradation product to predict poor one-year outcome of medically treated patients with acute type B aortic dissection.
MedLine Citation:
PMID:  18435968     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Previous studies have indicated that medical therapy provides excellent outcomes for patients with uncomplicated Stanford type B acute aortic dissection. However, affected aortas are often compromised by aneurysmal dilatation and rupture, resulting in poor outcomes. The purpose of this study was to determine predictors of aortic events in patients with Stanford type B acute aortic dissection receiving conservative medical therapy. The study group consisted of 78 consecutive patients with Stanford type B acute aortic dissection who were admitted to the hospital within 48 hours of onset. These patients were treated medically and followed up for 1 year. Aortic events were defined as rupture, recurrent dissection, aortic expansion with diameter>or=60 mm, rapid aortic expansion at a rate of >or=10 mm/yr, and the development of visceral or limb ischemia. Predictors of these events were determined using multivariate analyses. During 1-year follow-up, aortic events were observed in 13 (17%) patients, including aortic rupture in 3 (4%), aortic diameter>or=60 mm in 4 (5%), rapid expansion of the aorta in 3 (4%), and the development of visceral or limb ischemia in 3 (4%). On multivariate analysis, fibrinogen-fibrin degradation product level>or=20 microg/ml (odds ratio 7.802, 95% confidence interval 1.405 to 43.335) on admission was the only independent predictor of aortic events at 1 year. In conclusion, careful monitoring is required for patients with medically treated Stanford type B acute aortic dissection associated with fibrinogen-fibrin degradation product level>or=20 microg/ml on admission.
Authors:
Shuichi Kitada; Koichi Akutsu; Yuiichi Tamori; Tsuyoshi Yoshimuta; Hideki Hashimoto; Satoshi Takeshita
Related Documents :
7283518 - Surgical treatment of aneurysms of the transverse aortic arch: experience with 25 patie...
10647828 - Twenty-four year experience with reoperations after ascending aortic or aortic root rep...
10151018 - Results of balloon aortic valvuloplasty in patients with aortic stenosis associated wit...
8558768 - Aortic dissection in taiwan.
25399008 - Interventional treatment for structural heart disease: who is deciding, and can we affo...
22300068 - Adherence with migraine prophylaxis in clinical practice.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-03-07
Journal Detail:
Title:  The American journal of cardiology     Volume:  101     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2008 May 
Date Detail:
Created Date:  2008-04-25     Completed Date:  2008-06-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1341-4     Citation Subset:  AIM; IM    
Affiliation:
Department of Cardiology, National Cardiovascular Center, Suita, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Aged
Aneurysm, Dissecting / blood*,  therapy*
Aneurysm, Ruptured / blood*,  therapy*
Aortic Aneurysm / blood*,  therapy*
Chi-Square Distribution
Female
Fibrin Fibrinogen Degradation Products / analysis*
Humans
Male
Predictive Value of Tests
Proportional Hazards Models
Retrospective Studies
Survival Analysis
Treatment Outcome
Chemical
Reg. No./Substance:
0/Fibrin Fibrinogen Degradation Products

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Use of body weight and insulin resistance to select obese patients for echocardiographic assessment ...
Next Document:  Relation of left atrial maximal volume measured by real-time 3D echocardiography to demographic, cli...